Direct medical costs associated with using vancomycin in methicillin-resistant Staphylococcus aureus infections: an economic model

References

• Jones ME, Karlowsky JA, Draghi DC, et al. Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapy. Int J Antimicrob Agents 2003;22(4):406–19
   PubMed Web of Science ®Google Scholar
• Stefani S, Varaldo PE. Epidemiology of methicillin-resistant staphylococci in Europe. Clin Microbiol Infect 2003;9(12):1179
   PubMed Web of Science ®Google Scholar
• Haddadin AS, Fappiano SA, Lipsett PA. Methicillin resistant Staphylococcus aureus (MRSA) in the intensive care unit. Postgrad Med J 2002;78(921):385–92
   Google Scholar
• Johnston BL. Methicillin-resistant Staphylococcus aureus as a cause of community-acquired pneumonia – a critical review. Semin Respir Infect 1994;9(3):199–206
   PubMedGoogle Scholar
• National Nosocomial Infections Surveillance (NNIS) System Report. Data summary from January 1992 to April 2000. Am J Infect Control 2000;28: 429–48
   PubMed Web of Science ®Google Scholar
• Wilson WR, Karchmer AW, Dajani AS, et al. Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms. [American Heart Association]. J Am Med Assoc 1995;274(21):1706–13
   PubMed Web of Science ®Google Scholar
• Jarvis WR. Epidemiology, appropriateness, and cost of vancomycin use. Clin Infect Dis 1998;26(5):1200–3
   PubMed Web of Science ®Google Scholar
• Khare M, Keady D. Antimicrobial therapy of methicillin resistant Staphylococcus aureus infection. Expert Opin Pharmacother 2003;4(2):165–77
   PubMed Web of Science ®Google Scholar
• Gentry CA, Rodvold KA, Novak RM, et al. Retrospective evaluation of therapies for Staphylococcus aureus endocarditis. Pharmacotherapy 1997;17(5):990–7
   PubMed Web of Science ®Google Scholar
• Chambers HF, Miller RT, Newman MD. Right-sided Staphylococcus aureus endocarditis in intravenous drug abusers: two-week combination therapy. Ann Intern Med 1988;109(8):619–24
   Google Scholar
• Karchmer AW, Archer GL, Dismukes WE. Staphylococcus epidermidis causing prosthetic valve endocarditis: microbiologic and clinical observations as guides to therapy. Ann Intern Med 1983;98(4):447–55
   Google Scholar
• Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991;115(9):674–80
   PubMed Web of Science ®Google Scholar
• Li Z, Willke RJ, Pinto LA, et al. Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmacotherapy 2001;21(3):263–74
   PubMed Web of Science ®Google Scholar
• Stevens DL, Herr D, Lampiris H, et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002;34(11):1481–90
   PubMed Web of Science ®Google Scholar
• Dompeling EC, Donnelly JP, Deresinski SC, et al. Early identification of neutropenic patients at risk of Gram positive bacteraemia and the impact of empirical administration of vancomycin. Eur J Cancer 1996;32A(8):1332–9
   PubMed Web of Science ®Google Scholar
• Garrelts JC, Horst WD, Silkey B, et al. A pharmacoeconomic model to evaluate antibiotic costs. Pharmacotherapy 1994;14(4):438–45
   PubMed Web of Science ®Google Scholar
• Charbonneau P, Harding I, Garaud JJ, et al. Teicoplanin: a well-tolerated and easily administered alternative to vancomycin for Gram-positive infections in intensive care patients. Intensive Care Med 1994;20 (Suppl 4):S35–S42
   PubMedGoogle Scholar
• Wilhelm MP. Vancomycin. Mayo Clin Proc 1991;66:1165–70
   PubMed Web of Science ®Google Scholar
• Pallares R, Dick R, Wenzel RP, et al. Trends in antimicrobial utilization at a tertiary teaching hospital during a 15-year period (1978–1992). Infect Control Hosp Epidemiol 1993;14(7):376–82
   PubMed Web of Science ®Google Scholar
• Cunha BA. Vancomycin. Med Clin North Am 1995;79(4): 817–31
   PubMed Web of Science ®Google Scholar
• Kralovicova K, Spanik S, Halko J, et al. Do vancomycin serum levels predict failures of vancomycin therapy or nephrotoxicity in cancer patients? J Chemother 1997;9(6):420–6
   PubMed Web of Science ®Google Scholar
• Cohen E, Dadashev A, Drucker M, et al. Once-daily versus twice-daily intravenous administration of vancomycin for infections in hospitalized patients. J Antimicrob Chemother 2002;49(1):155–60
   PubMed Web of Science ®Google Scholar
• Beringer PM, Wong-Beringer A, Rho JP. Economic aspects of antibacterial adverse effects. Pharmacoeconomics 1998;13(Pt 1):35–49
   PubMed Web of Science ®Google Scholar
• Duffull SB, Begg EJ. Vancomycin toxicity. What is the evidence for dose dependency? Adverse Drug React Toxicol Rev 1994;13(2):103–14
   PubMedGoogle Scholar
• Holloway JJ, Smith CR, Moore RD, et al. Comparative cost effectiveness of gentamicin and tobramycin. Ann Intern Med 1984;101(6):764–9
   PubMed Web of Science ®Google Scholar
• Elting LS, Rubenstein EB, Kurtin D, et al. Mississippi mud in the 1990s: risks and outcomes of vancomycin-associated toxicity in general oncology practice. Cancer 1998;83(12):2597–607
   PubMed Web of Science ®Google Scholar
• Sorrell TC, Collignon PJ. A prospective study of adverse reactions associated with vancomycin therapy. J Antimicrob Chemother 1985;16(2):235–41
   PubMed Web of Science ®Google Scholar
• Cantu TG, Yamanaka-Yuen NA, Lietman PS. Serum vancomycin concentrations: reappraisal of their clinical value. Clin Infect Dis 1994;18(4):533–43
   PubMed Web of Science ®Google Scholar
• McEvoy GK. AHFS drug 2002 information. Bethesda: American Society of Health Pharmacist, Inc; 2002
   Google Scholar
• Tam VH, Moore GE, Triller DM, et al. Vancomycin peak serum concentration monitoring. J Intraven Nurs 1999;22(6):336–42
   PubMedGoogle Scholar
• Williams DN, Rehm SJ, Tice AD, et al. Practice guidelines for community-based parenteral anti-infective therapy. [ISDA Practice Guidelines Committee]. Clin Infect Dis 1997;25(4):787–801
   PubMed Web of Science ®Google Scholar
• Cunha BA. Intravenous-to-oral antibiotic switch therapy: a cost-effective approach. Postgraduate Medicine 1997;101(4)
   Web of Science ®Google Scholar
• Bucaneve G, Menichetti F, Del Favero A. Cost analysis of 2 empiric antibacterial regimens containing glycopeptides for the treatment of febrile neutropenia in patients with acute leukaemia. Pharmacoeconomics 1999;15(1):85–95
   Google Scholar
• Karam CM, McKinnon PS, Neuhauser MM, et al. Outcome assessment of minimizing vancomycin monitoring and dosing adjustments. Pharmacotherapy 1999;19(3):257–66
   PubMed Web of Science ®Google Scholar
• Abad F, Calbo F, Zapater P, et al. Comparative pharmaco-economic study of vancomycin and teicoplanin in intensive care patients. Int J Antimicrob Agents 2000; 15(1):65–71
   PubMed Web of Science ®Google Scholar
• Fernandez de Gatta MD, Calvo MV, Hernandez JM, et al. Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies. Clin Pharmacol Ther 1996;60(3):332–40
   PubMed Web of Science ®Google Scholar
• Welty TE, Copa AK. Impact of vancomycin therapeutic drug monitoring on patient care. Ann Pharmacother 1994;28(12):1335–9
   PubMed Web of Science ®Google Scholar
• National Evaluation of the Cost Effectiveness of Home Care HCEaRC. An economic evaluation of hospital-based and home-based intravenous antibiotic therapy for individuals with cellulitis. 2001
   Google Scholar
• Rybak MJ. Teicoplanin vs vancomycin: cost-effectiveness comparisons. Hosp Formul 1993;28(Suppl 1):28–32
   PubMedGoogle Scholar
• Rodvold KA, Everett JA, Pryka RD, et al. Pharmacokinetics and administration regimens of vancomycin in neonates, infants and children. Clin Pharmacokinet 1997;33(1):32–51
   PubMed Web of Science ®Google Scholar
• Rubinstein E, Isturiz R, Standiford HC, et al. Worldwide assessment of linezolid’s clinical safety and tolerability: comparator-controlled phase III studies. Antimicrob Agents Chemother 2003;47(6):1824–31
   PubMed Web of Science ®Google Scholar
• Rolston KV, Bodey GP, Chow AW. Prospective, double-blind, randomized trial of teicoplanin versus vancomycin for the therapy of vascular access-associated bacteremia caused by Gram-positive pathogens. J Infect Chemother 1999;5(4):208–12
   Google Scholar
• Khurana C, de Belder MA. Red-man syndrome after vancomycin. Postgrad Med J 1999;75(879):41–3
   PubMed Web of Science ®Google Scholar
• Geraci JE, Wilson WR. Vancomycin therapy for infective endocarditis. Rev Infect Dis 1981;(3 Suppl):S250–S258
   Google Scholar
• Small PM, Chambers HF. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 1990;34(6):1227–31
   PubMed Web of Science ®Google Scholar
• Fortun J, Navas E, Martinez-Beltran J, et al. Short-course therapy for right-side endocarditis due to Staphylococcus aureus in drug abusers: cloxacillin versus glycopeptides in combination with gentamicin. Clin Infect Dis 2001;33(1):120–5
   Google Scholar
• Merrill DFP, editor. The hospital anti-infective market guide, US ed. Book one: drug reports. Malvern, PA: Arlington Medical Resources I; 2002
   Google Scholar
• Graham JC, Gould FK. Role of aminoglycosides in the treatment of bacterial endocarditis. J Antimicrob Chemother 2002;49(3):437–44
   PubMed Web of Science ®Google Scholar
• Farber BF, Moellering Jr. RC. Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother 1983;23(1):138–41
   Google Scholar
• Muilenburg N. Management of fibromyalgia. Ann Intern Med 2000;132(12):1004–5
   PubMedGoogle Scholar
• Vance-Bryan K, Rotschafer JC, Gilliland SS, et al. A comparative assessment of vancomycin-associated nephrotoxicity in the young versus the elderly hospitalized patient. J Antimicrob Chemother 1994;33(4):811–21
   Google Scholar
• Rybak MJ, Albrecht LM, Boike SC, et al. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother 1990;25(4):679–87
   PubMed Web of Science ®Google Scholar
• Pauly DJ, Musa DM, Lestico MR, et al. Risk of nephrotoxicity with combination vancomycin–aminoglycoside antibiotic therapy. Pharmacotherapy 1990;10(6):378–82
   PubMed Web of Science ®Google Scholar
• Goetz MB, Sayers J. Nephrotoxicity of vancomycin and aminoglycoside therapy separately and in combination. J Antimicrob Chemother 1993;32(2):325–34
   PubMed Web of Science ®Google Scholar
• Antony SJ, Ladner J, Stratton CW, et al. High-level aminoglycoside-resistant enterococcus causing endocarditis successfully treated with a combination of ampicillin, imipenem and vancomycin. Scand J Infect Dis 1997;29(6):628–30
   PubMed Web of Science ®Google Scholar
• Green SL, Maddox JC, Huttenbach ED. Linezolid and reversible myelosuppression. J Am Med Assoc 2001;285(10):1291
   PubMed Web of Science ®Google Scholar
• 2003 National fee analyzer: In: Charge data for evaluating fees nationwide. [Ingenix, editor. 2003]. Salt Lake City
   Google Scholar
• Drug topics red book, vol. 22, No. 30. Montvale: Medical Economics Company; 2003
   Google Scholar
• Coleman CI, Reddy P, Kalus JS, et al. The impact of prophylactic manesium on cost of therapy, efficacy, and adverse drug reactions in patients receiving ibutilide for chemical cardioversion of atrial fibrillation. American Society of Health-Systems Pharmacists Annual Meeting. Atlanta, GA; 2002
   Google Scholar
• Average Salary Plus Benefits. http://www.salary.com/salary/layoutscripts/sall_display.asp. [Accessed March 2003]
   Google Scholar
• Paladino JA, Gudgel LD, Forrest A, et al. Cost-effectiveness of IV-to-oral switch therapy: azithromycin vs cefuroxime with or without erythromycin for the treatment of community-acquired pneumonia. Chest 2002;122(4):1271–9
   PubMed Web of Science ®Google Scholar
• Goldstein E, Bartholomew WR, Vickers MK, et al. Are serum levels of vancomycin useful in the first week of therapy? Mo Med 1995;92(9):596–9
   PubMedGoogle Scholar
• National Average of ICU Cost 2003
   Google Scholar
• Tice AD, Hoaglund MSN, Nolet B, et al. Cost perspectives for oupatient intravenous antimicrobial therapy. Pharmacotherapy 2002;22(2):63S-70S
   Google Scholar
• Bernard L, El H Pron B, Lotthe A, et al. Outpatient parenteral antimicrobial (OPAT) for the treatment of osteomyelitis: evaluation of efficacy, tolerance, and cost. J Clin Pharm Ther 2001;26:445–51
   PubMed Web of Science ®Google Scholar
• Reddy P, Dunn AB, White CM, et al. An economic analysis of amiodarone versus placebo for the prevention of atrial fibrillation after open heart surgery. Pharmacotherapy 2002;221(1):75–80
   Google Scholar
• Webb M, Riley LW, Roberts RB. Cost of hospitalization for and risk factors associated with vancomycin-resistant Enterococcus faecium infection and colonization. Clin Infect Dis 2001;33(4):445–52
   PubMed Web of Science ®Google Scholar
• Carmeli Y, Samore MH, Huskins C. The association between antecedent vancomycin treatment and hospital-acquired vancomycin-resistant enterococci: a meta-analysis. Arch Intern Med 1999;159(20):2461–8
   Google Scholar
• Carbon C. Costs of treating infections caused by methicillin-resistant staphylococci and vancomycin-resistant enterococci. J Antimicrob Chemother 1999; 44(Suppl A):31–6
   Google Scholar
• McGeer AJ, Low DE. Vancomycin-resistant enterococci. Semin Respir Infect 2000;15(4):314–26
   PubMedGoogle Scholar
• Zanetti G, Goldie SJ, Platt R. Clinical consequences and cost of limiting use of vancomycin for perioperative prophylaxis: example of coronary artery bypass surgery. Emerg Infect Dis 2001;7(5):820–7
   Google Scholar
• Geraci JE, Heilman DR, Nichols DR, et al. Antibiotic therapy for bacterial endocarditis (VII): vancomycin for acute micrococcal endocarditis. In: Proceedings of the Staff Meetings of the Mayo Clinic 1958;33:172–81
   PubMed Web of Science ®Google Scholar